Available for almost 2 decades, the 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors, or statins, have emerged at the forefront of preventive drugs for cardiovascular …

In a cohort of patients hospitalized for myocardial infarction (MI) at high death risk, Serban et
al.(1) found that statin intolerance was common in the year after initiation of therapy and that …

1327 Comparative Study of 3 Strong Statins ferase (ALT) was observed more frequently with
atorvastatin than with the other 2 statins. Although this significant difference diluted toward …

The 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase inhibitors or statins are the most
successful cardiovascular drugs of all time. By interrupting cholesterol synthesis in the liver …

With the strong correlation between the development of coronary heart disease and
elevated levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) …

Statins are first-line therapy for reducing low-density lipoprotein (LDL) levels in patients at
high risk for atherosclerotic cardiovascular disease (ASCVD). 1, 2 These agents are being …

The development of “Top 5” lists across specialties and at regular intervals can help to
remind physicians that optimal care is often possible at a lower cost. For purposes of …

This announcement is not a result of a sudden epidemic of heart disease, nor is it based on
new data showing the benefits of lower cholesterol. Instead, it is a consequence of simply …

Musculoskeletal symptoms are the most common AEs reported by patients who are taking
statins. 5 These range from muscle weakness, fatigue, and pain to (rarely) rhabdomyolysis …

The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statin
drugs, have been studied in numerous controlled human research trials involving hundreds …